# Celularity to acquire Alliqua BioMedical's wound care business for $29M

Alliqua BioMedical announced a definitive agreement for Celularity to acquire its advanced biologic wound care business and therapeutic ultrasound platform products for $29 million in cash. The transaction is subject to stockholder approval.

- Type: Acquisition
- Announced: 2018-01-05
- Where: Yardley, Pennsylvania, United States
- Value: $29.0M
- Status: announced
- Products: Biovance amniotic membrane allograft, Interfyl Human Connective Tissue Matrix, UltraMist Therapy System
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Alliqua BioMedical](https://endata.com/companies/26738.md) (target)
- [Celularity](https://endata.com/companies/29219.md) (acquirer)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2018/01/05/1284389/0/en/alliqua-biomedical-inc-announces-definitive-asset-purchase-agreement-with-celularity-inc.html), 2018-01-05: "This is a transformative transaction for Alliqua."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.